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I
n its effort to develop worldwide 
standards of trial registration, the 
World Health Organization (WHO) 
has formally launched its International 
Clinical Trials Registry Platform 
(ICTRP) project. The project is “taking 
the lead in setting international norms 
and standards for trial registration and 
reporting” [1]. 
As part of the project, on 25–27 
April 2005, the WHO organized a 
technical consultation on clinical 
trial registration standards. The 
outcome of this consultation included 
a deﬁ  nition of the type of trials that 
need to be registered, and also of a 20 
item “minimal dataset” (outlining 20 
characteristics of the trial) that needs 
to be registered. The project has, in 
addition, decided to establish a unique 
identiﬁ  er scheme [1], and to develop a 
worldwide search portal for trials. 
Unfortunately, the pharmaceutical 
industry arrived at that meeting with 
an already established position that ﬁ  ve 
items in the minimal dataset are often 
commercially sensitive. Hence, for 
some of its trials, the industry proposed 
to either delay these items’ public 
disclosure or not make them publicly 
available at all. It proposed instead to 
allow them to be held in escrow, to be 
seen by medical journal editors at the 
time of manuscript evaluation, or just 
shown to the WHO [2].
However, even the proposed 
minimal dataset leaves out many 
of the crucial items in the Ottawa 
Statement on principles for trial 
registration (http:⁄⁄ottawagroup.ohri.
ca/statement.html) published by the 
Ottawa Group, which consists of over 
100 individuals and organizations 
worldwide (http:⁄⁄ottawagroup.ohri.
ca/signatories.html).
In this article, I brieﬂ  y consider the 
origins of the global movement for trial 
registration, and then compare the 
three different approaches taken by the 
pharmaceutical industry, the ICTRP, 
and the Ottawa Group (Table 1).
Why We Need Trial Registration 
The need for trial registration has 
been recognized for years. However, its 
urgency became particularly apparent in 
2004 with the revelation that trial data on 
the harms of speciﬁ  c serotonin reuptake 
inhibitors in children went undisclosed 
[3]. The importance of registering trials 
has been made clear, for example, by 
the attorney general of New York’s legal 
action against GlaxoSmithKline [4], 
and by the decision of medical journal 
editors (including the editors of PLoS 
Medicine and PLoS Clinical Trials) not 
to publish any trial unless it is has been 
registered [5–7]. 
Transparency in research and 
knowledge sharing are now widely seen 
as a precondition for the success of 
the health research enterprise. Trial 
registries are an important tool to 
help achieve this transparency. Just as 
research methodology evolved due to 
advances in technology, so the Internet 
has made electronic registries entirely 
feasible. The vision of freely accessible 
electronic depositories of protocol 
information of ongoing trials and 
their results, with each trial assigned 
a unique number so that it can be 
tracked, is now achievable.
Trial Registries
Many registries have been developed 
to meet various speciﬁ  c needs. Here 
I will brieﬂ  y present two that have 
been important in the discussions 
and decision-making processes of 
the WHO, the Ottawa Group, and 
the International Committee of 
Medical Journal Editors (ICMJE). 
These registries are the International 
Standard Randomized Controlled Trial 
Number (ISRCTN) register, available 
at http:⁄⁄www.controlled-trials.com/
isrctn/, and ClinicalTrials.gov, run 
by the National Library of Medicine 
(NLM) at http:⁄⁄www.clinicaltrials.
gov/. They both have accumulated 
practical experience by existing for 
more than ﬁ  ve years. Although starting 
from different points, and having some 
different speciﬁ  c goals, they overlap 
on the important registration premise 
to provide free electronic access to 
deposited, essential information of 
ongoing trials. In summary, ISRCTN 
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Box 1. Principles Outlined in 
Part 1 of the Ottawa Statement
• Objective
• Deﬁ  nitions
• Rationale for international trial 
registration
• Types of trials to be registered
• Elements of registration
• Principles relating to unique ID, protocol 
registration, and registration of trial 
results
• Organization and language of registries
• Responsibilities of involved partiesPLoS Medicine  |  www.plosmedicine.org 1094
was created between 1998 and 2000 
by a working group of researchers, 
mainly systematic reviewers, organized 
by the publisher Current Science 
Group (http:⁄⁄www.controlled-trials.
com/information/faqs.asp), whereas 
ClinicalTrials.gov was formed ﬁ  ve years 
ago by the NLM to meet United States 
legal requirements, and, as required by 
the US Food and Drug Administration 
(FDA) or US law, to enable a portal 
to register drug-related trials in the 
area of serious and life-threatening 
disease, and to enable potential 
participants to identify such studies in 
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Table 1. Comparison of Trial Registration Protocol Items Proposed by the Pharmaceutical Industry, the WHO, and the Ottawa Group
WHO Item 
Number
Joint Pharmaceutical Companies’ 
Positiona
WHOb Ottawa Group Proposedc
N/A All clinical trials other than exploratory All prospective trials other than exploratoryd All  trials
1 Unique ID Primary register and trial ID number (former 
unique ID) 
Unique ID
2 Date of registration in primary register  Key trial dates (registration, ethics approval, recruitment 
start, recruitment end, follow-up end, trial stopped, and 
trial extended)
3 Other Trial IDs Secondary IDs
4 Funding source Funding source(s)
5 Primary sponsor Primary sponsor
6 Secondary sponsor Secondary sponsor
7 Responsible contact person (public contact) Responsible contact person
8 Lead principal investigator Principal investigator(s)
9 Brief title Public title Brief title
Lay description Acronym
Trial Web site
Short lay description (text)
10 Scientiﬁ  c title (including intervention name, 
condition, and primary outcome)
Ofﬁ  cial scientiﬁ  c title
11 Research Ethics Review Board approval  Ethics approval: Research Ethics Review Board; yes/no-
which body, and the date (see key trial dates)
12 Condition or disease Disease or condition studied Disease or condition
Trial objectives
Trial type (e.g., intervention, drug, or 
vaccine)
Study type (e.g., intervention, drug, device, vaccine, 
behaviour, complementary)
Trial purpose (e.g., diagnosis, prevention, 
and therapy)
1 Trial purpose (e.g., therapy, diagnosis, prevention, and 
device)
13 Intervention(s) with duration of intervention Interventions (all interventions, in all trial arms, both test 
intervention[s] and comparison[s] with duration)
14 Key eligibility criteria including gender 
and age 
(Key)e inclusion and exclusion criteria Eligibility criteria (full list, lay version [text])
15 Trial phase (exploratory, hypothesis testing) Study type: randomized controlled (formerly, 
ClinTrials.gov list interventional, or observational)
Design (single group, parallel, crossover, factorial, and 
expanded access)
Framework (superiority, noninferiority, equivalence, and 
dose ranging)
Randomized or not
Phase of trial (1–4, or other descriptor)
16 Date of ﬁ  rst enrolment (estimated date of 
enrolment of the ﬁ  rst study participant)
Recruitment start date (see key trial dates)
17 Target sample size Target sample size
Location of trial Trial locations (recruiting and resource centers)
18 Trial status Recruitment status at time of clinical trial unique 
ID (CT-UID) request
Recruitment status
19 Primary outcomes and time of measurement or 
time to completion
All primary outcomes, both variable name and time 
points measured
20 (Key)e Secondary outcomes and time to 
measurement or time to completion
Secondary or additional outcomes (list all other 
outcomes to be examined including subgroup analyses 
and adverse events; list both variable names and time 
points measured)
Study consent form approved by research ethics reviews 
board
Study data collection forms (PDFs of all study data 
collection forms) 
a Joint position found at [1].
b Current version available at http://www.who.int/ictrp/en/.
c Extract from the background material used by the Ottawa Group for its discussion on the implementation of principles of trial registration in Portland, Oregon (23 May 2005).
d The WHO expressed in May 2005 that registration of exploratory trials was strongly encouraged but not mandatory.
e The word “key” which was present in the May 2005 version has been eliminated from the current version.
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order to participate in them. The US 
National Institutes of Health, through 
NLM, has developed this Web site in 
collaboration with the FDA as a result 
of the FDA Modernization Act, which 
was passed into law in November 1997 
[8,9]. Since 2004, and in response to 
recent intensive international dialogue, 
each registry has been changing as 
needed in various ways: expanding 
their ﬁ  elds, becoming publicly owned, 
or accepting registration of all trials.
The Importance of Knowledge 
Sharing
Unfortunately, most current ongoing 
trials are not built on all existing 
knowledge because all knowledge 
is not made publicly available—it 
remains hidden in different pockets by 
various interested entities. This lack of 
knowledge sharing is an obstacle to the 
further creation of knowledge. Even 
when (some) clinical trial information 
is shared, the sharing is often delayed 
until a drug is on the market or, in 
a somewhat better case, until the 
trial is published. It typically takes 
10–15 years between the initial idea 
for a trial—formulating and testing 
the idea, developing a trial protocol, 
peer reviewing, gaining funding and 
ethics approval, implementing the 
trial, developing the consequent 
intervention (including a drug)—and 
making it available to those who need 
it. Thus, we might have to wait up to 
15 years to learn about a given trial. 
However, if the trial is never published, 
or if further studying is abandoned for 
whatever reason, this information has a 
high chance of never being shared.
Such a delay in disclosing ongoing 
trials means that several different 
research teams may be studying the 
same thing simultaneously in isolation, 
and, hence, are not building on the 
existing evidence but rather working 
on a part of the currently available 
evidence. Precious time and resources 
are wasted. More importantly, trial 
participants may be unnecessarily 
exposed to risk if the substance studied 
has harmful effects that have not (yet) 
been disclosed. Above all, research 
on humans can only be justiﬁ  ed if the 
knowledge arising from that research 
is made publicly available for the 
public good. Only by registering trials 
prospectively can we be sure that all 
trials that are undertaken are also 
reported.
International Interest in Trial 
Registration: The Ottawa Group
Given the importance of knowledge 
sharing, an international group of 
those interested in trial registration, 
including systematic reviewers 
and pharmaceutical industry 
representatives, began a dialogue on 
trial registration in Ottawa, Canada, 
during the Cochrane Colloquium in 
October 2004 [10]. This meeting was 
initiated by the Canadian Institutes 
of Health Research—a neutral 
but interested party that has been 
registering the trials it funds [11].
The aim of the Ottawa Group 
dialogue is to discuss and reach global 
consensus on trial registration, and to 
understand the meaning of registration 
for the group members’ professional 
lives, for research, and for medicine 
and health in general. 
The October 2004 meeting led 
to part I of the Ottawa Statement 
[10], summarized in Box 1. The 
statement has also been translated 
into and published in Japanese [12], 
and other translations are under 
way. The principles in this statement 
are simple and clear: disclose the 
protocol details of all trials up front, 
disclose amendments along the 
way, and post the results at the end 
(http:⁄⁄ottawagroup.ohri.ca/statement.
html). Part I was used in the WHO-
led worldwide consensus building 
while a dialogue continues, and part 
II of the statement, which discusses 
implementation principles, will follow. 
The Pharmaceutical Industry’s 
Response
The Ottawa Statement has received 
endorsements from over 100 
individuals and groups on all ﬁ  ve 
continents, but so far there has not 
been a single signatory from a drug 
company (the list of signatories is 
available at http:⁄⁄ottawagroup.ohri.
ca/signatories.html). This failure of 
endorsement by the pharmaceutical 
industry was unexpected since 
the Ottawa Statement proposes 
principles of trial registration, and 
its endorsement does not mean 
that any company would need to 
start implementing these principles 
immediately and begin registering all 
details of all trials right away. 
The closest that anyone from 
the pharmaceutical industry has 
come to endorsing the principles 
of trial registration are Jesse A. 
Berlin (Johnson and Johnson) in his 
commentary, “Why Industry Should 
Register and Disclose Results of 
Clinical Studies—Perspective of a 
Recovering Academic” [13]. While 
Ronald Krall and Frank Rockhold 
in their letter, “GSK Has Created 
Useful Register” [14], hinted at such 
a possibility, in a subsequent letter 
by Krall and Rockhold as a reaction 
to the publication of part I of the 
Ottawa Statement, they stated that 
while “we reiterate our support for 
the principle of transparency,” the 
authors believed, “there is reason for 
concern about the amount of detail 
called for by the Statement” [15]. Both 
letters reﬂ  ect clearly the January 2005 
pharmaceutical industry statement [2], 
reconﬁ  rmed again in September 2005 
[16], and mostly concentrate on the 
industry’s concern about the disclosure 
of protocol details of early, so-called 
hypothesis-creating trials. 
Although this lack of endorsement 
by the industry might imply that the 
Ottawa principles are reaching too far, 
this is not the case. For example, the 
minimum set of data items proposed by 
the Ottawa Statement is already on the 
electronic National Institute of Health/
NLM ClinicalTrials.gov register, 
with which the industry is familiar. 
Rather, this lack of endorsement by 
the industry explains the ﬁ  elds left 
empty or ﬁ  lled in with meaningless 
information by certain pharmaceutical 
companies in these registries (D. 
Zarin [Director of ClinicalTrials.gov], 
personal communication; [17]). Using 
Zarin’s analysis in May 2005, the ICMJE 
stated, “Many entries in the publicly 
accessible ClinicalTrials.gov database 
do not provide meaningful information 
in some key data ﬁ  elds,” and demanded 
the validation of registration data [17].
The WHO ICTRP Minimal Dataset 
Several members of the Ottawa Group 
were among many participants at 
the WHO technical consultation on 
clinical trial registration standards 
in April 2005. Other participants 
included medical journal editors, 
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pharmaceutical companies, and the two 
major registries, ClinicalTrials.gov and 
the ISRCTN register.
A major outcome of this consultation 
was the previously mentioned 20 item 
minimal dataset for trial registration. 
This dataset has formally been 
supported by the ICMJE [17].
However, as mentioned, full up 
front disclosure of ﬁ  ve of these 20 
key items is being challenged by the 
pharmaceutical industry [18]. The 
ﬁ  ve items that industry disagrees with 
the automatic public disclosure of are 
the ofﬁ  cial scientiﬁ  c title of the study 
(item 10), the intervention (item 13), 
the target sample size (item 17), the 
primary outcome (item 19), and the 
key secondary outcomes (item 20). The 
industry has agreed, instead, to place 
these ﬁ  ve hidden items for an unknown 
proportion of trials in escrow—that is, 
into an electronic depository that the 
public cannot access or will only be able 
to access with a delay. Table 1 gives a 
comparison of the minimum registration 
data laid out by the WHO ICTRP project 
and the pharmaceutical industry, and 
proposed by the Ottawa Group.
This comparison of the ICTRP 
and Ottawa statements shows that 
the requirements of the ICTRP 
statement are less far reaching. The 
ICTRP statement seems to reﬂ  ect 
the industry’s concerns in that the 
wording of 15 out of 20 items agreed 
on by the WHO ICTRP project in 
April 2005 is similar to those agreed 
on by pharmaceutical companies in 
its January 2005 industry statement 
[1,2]. The document arising from 
the WHO technical consultation also 
states that “one or more of data items 
10, 13, 17, 19, 20 may be regarded as 
sensitive for competitive reasons by the 
sponsor who may wish to delay release 
of the information” [18]. However, 
the WHO’s current proposal is that 
to get registered and obtain a unique 
identiﬁ  cation (ID), all 20 items must 
be provided to the WHO. Although the 
ICTRP statement is a great beginning 
to this WHO project, which aims to be 
a compromise between the differing 
positions on public disclosure, the 
Ottawa Statement should be seen as the 
goal to which we should aspire.
Why Are All Twenty Items Essential 
to Understand a Trial?
The pharmaceutical industry claims 
[1,16] that a disclosure of one or all ﬁ  ve 
data items would endanger proprietary 
rights, or as Krall and Rockhold put it, 
“jeopardize the competitive investment 
which underlines the creation of new 
medicines” [15]. But in reality, the 
lack of public availability of the ﬁ  ve 
key data items raises many problematic 
issues—for example, it would need to 
be clear who would approve the reason 
for withholding a data item from 
the public or the decision about the 
eventual timing of disclosure. 
The twenty items complement 
each other, and arguably provide 
the very minimum dataset needed 
to understand an ongoing trial. One 
of these items is the unique ID, nine 
are administrative, and ten are trial 
descriptors, the disclosure of ﬁ  ve of 
which are being challenged by the 
industry. This leaves us with only ﬁ  ve 
trial descriptors as follows: brief title, 
condition, key inclusion criteria, study 
type, and recruitment status. Looking 
at these ﬁ  ve items, it becomes clear 
that they alone are not sufﬁ  cient to 
provide meaningful information about 
any given trial, and would make trial 
registration meaningless to the public; 
i.e., although these data may have been 
provided to the register and made 
available to editors, if they are not 
publicly available, it will be impossible 
for anyone else to understand the trial.
Table 2 illustrates what the 
description of a trial might look like 
with the ﬁ  ve disputed trial descriptors 
omitted. For clarity, I also omitted 
some administrative data items (Table 
2). Evidently, we do not know very 
much about this trial. 
Trial registration has multiple 
functions, from a registry being a 
recruitment tool to being a means to 
fulﬁ  ll legal obligations (I have already 
mentioned the FDA requirement of 
registration in case of serious and 
life-threatening diseases) to broad 
knowledge sharing, i.e., full disclosure. 
By mutually complementing each 
other, full public disclosure of the 
proposed WHO 20-item minimal 
registry set would meet all three main 
functions; without this, registration 
will not fulﬁ  ll some of these functions. 
So although, as pointed out by the 
pharmaceutical industry [19], these 15 
remaining items might seem sufﬁ  cient 
for recruitment of trial participants, 
they do not meet scientiﬁ  c and ethical 
criteria; hence, all 20 are essential for 
trial registration. 
Conclusion
Knowledge sharing is crucial to health 
research, and trial registration is an 
indispensable part of such sharing. It is 
important that standards for universal 
trial registration be deﬁ  ned and 
applied globally. 
At present, there are clearly 
major differences among various 
interested parties concerning which 
trial characteristics must be made 
publicly available at registration. As 
these different parties are all partners 
and stakeholders in the clinical trials 
research enterprise, they need to ﬁ  nd 
a compromise between proprietary 
interests and knowledge sharing. I 
believe that new ways will have to 
be developed to protect intellectual 
and commercial interests and rights, 
without harming the public interest. 
There will have to be a change in 
attitudes to deal with this issue. We 
have indicated this need for change 
leading to a new paradigm of health 
research based on transparency, full 
disclosure, and collaboration in our 
earlier paper [10]. We have to keep 
in mind that although protection of 
commercial interests is important, the 
social contract with trial participants 
must surely take precedence.
As these compromises are worked 
out, journal editors stand ﬁ  rm in their 
position of requiring a precise trial 
registration, following the WHO–
ICRTP standards. In its effort to move 
Table 2. An Imaginary Breast Cancer Study with Only the Remaining Trial Descriptors 
WHO Item Number Remaining Trial Descriptors Potential Trial Description 
1 Unique trial number  12345
9 Brief trial title  New breast cancer therapy
12 Condition Breast cancer
14 Key inclusion /exclusion criteria Women aged 35–65; nonsmokers
15 Study type Double-blind, parallel placebo
16 Anticipated start date July 2005
18 Recruitment status Currently recruiting
DOI: 10.1371/journal.pmed.0020378.t002
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the initiative forward following the 
April 2005 meeting, the WHO issued 
the invitation to review and provide 
comments on three outstanding items: 
clariﬁ  cation of the WHO Registration 
Data Set (the “20 items”); criteria for 
register certiﬁ  cation; and the unique 
ID assignment process, all of which 
are available in the “open comments” 
section on its Web site, available at 
http:⁄⁄www.who.int/ictrp. 
The Ottawa Group is also continuing 
its worldwide dialogue on principles of 
operationalization of trial registration, 
and it will continue to contribute to the 
global, intergovernmental efforts of the 
WHO. The group holds its next face-to-
face meeting in Melbourne, Australia, 
during the Cochrane Colloquium on 
24 October 2005.  
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